Cambridge, United Kingdom

Paul William Thompson

This inventor holds 2 USPTO granted patents and 6 published patent applications and 3 EPO patents. Top assignee: Mission Therapeutics Limited. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paul William Thompson. Retrieved from https://idiyas.com/inventor/paul-william-thompson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.4

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Paul William Thompson - Innovator in Therapeutic Solutions

Introduction

Paul William Thompson is an inventor based in Cambridge, GB. He is currently associated with Mission Therapeutics Limited, where he focuses on developing innovative therapeutic solutions. Despite having no granted patents to his name, Thompson is actively engaged in research and development in the field of medicine.

Latest Patent Applications

Thompson's latest patent applications include:

1. **N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS** - This invention relates to a class of N-cyanopyrrolidines that act as inhibitors of the deubiquitylating enzyme USP30. These compounds have potential utility in various therapeutic areas, including conditions involving mitochondrial dysfunction, cancer, and fibrosis.

2. **N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION** - This application also pertains to a class of N-cyanopyrrolidines with activity as inhibitors of USP30, aimed at addressing mitochondrial dysfunction, cancer, and fibrosis.

Conclusion

Paul William Thompson is a dedicated inventor contributing to the field of therapeutic innovations through his research at Mission Therapeutics Limited. His work on USP30 inhibitors showcases his commitment to addressing critical health challenges.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…